vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and CPI Card Group Inc. (PMTS). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $153.1M, roughly 1.2× CPI Card Group Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 4.8%, a 8.5% gap on every dollar of revenue. On growth, CPI Card Group Inc. posted the faster year-over-year revenue change (22.3% vs -1.8%). CPI Card Group Inc. produced more free cash flow last quarter ($35.2M vs $24.6M). Over the past eight quarters, CPI Card Group Inc.'s revenue compounded faster (16.9% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
CPI Card Group Inc. is a leading provider of payment card production and associated solutions, including contactless and contact credit/debit cards, prepaid cards, and card personalization services. It primarily serves financial institutions, fintech firms, and retail brands across its core North American market.
AMPH vs PMTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $153.1M |
| Net Profit | $24.4M | $7.3M |
| Gross Margin | 46.8% | 31.5% |
| Operating Margin | 19.4% | 12.0% |
| Net Margin | 13.3% | 4.8% |
| Revenue YoY | -1.8% | 22.3% |
| Net Profit YoY | -35.7% | 8.5% |
| EPS (diluted) | $0.51 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $153.1M | ||
| Q3 25 | $191.8M | $138.0M | ||
| Q2 25 | $174.4M | $129.8M | ||
| Q1 25 | $170.5M | $122.8M | ||
| Q4 24 | $186.5M | $125.1M | ||
| Q3 24 | $191.2M | $124.8M | ||
| Q2 24 | $182.4M | $118.8M | ||
| Q1 24 | $171.8M | $111.9M |
| Q4 25 | $24.4M | $7.3M | ||
| Q3 25 | $17.4M | $2.3M | ||
| Q2 25 | $31.0M | $518.0K | ||
| Q1 25 | $25.3M | $4.8M | ||
| Q4 24 | $38.0M | $6.8M | ||
| Q3 24 | $40.4M | $1.3M | ||
| Q2 24 | $37.9M | $6.0M | ||
| Q1 24 | $43.2M | $5.5M |
| Q4 25 | 46.8% | 31.5% | ||
| Q3 25 | 51.4% | 29.7% | ||
| Q2 25 | 49.6% | 30.9% | ||
| Q1 25 | 50.0% | 33.2% | ||
| Q4 24 | 46.5% | 34.1% | ||
| Q3 24 | 53.3% | 35.8% | ||
| Q2 24 | 52.2% | 35.7% | ||
| Q1 24 | 52.4% | 37.1% |
| Q4 25 | 19.4% | 12.0% | ||
| Q3 25 | 13.2% | 9.4% | ||
| Q2 25 | 24.2% | 7.3% | ||
| Q1 25 | 21.9% | 11.5% | ||
| Q4 24 | 24.2% | 12.7% | ||
| Q3 24 | 29.8% | 14.3% | ||
| Q2 24 | 30.3% | 12.5% | ||
| Q1 24 | 27.9% | 12.6% |
| Q4 25 | 13.3% | 4.8% | ||
| Q3 25 | 9.0% | 1.7% | ||
| Q2 25 | 17.8% | 0.4% | ||
| Q1 25 | 14.8% | 3.9% | ||
| Q4 24 | 20.4% | 5.4% | ||
| Q3 24 | 21.1% | 1.0% | ||
| Q2 24 | 20.8% | 5.1% | ||
| Q1 24 | 25.1% | 4.9% |
| Q4 25 | $0.51 | $0.62 | ||
| Q3 25 | $0.37 | $0.19 | ||
| Q2 25 | $0.64 | $0.04 | ||
| Q1 25 | $0.51 | $0.40 | ||
| Q4 24 | $0.74 | $0.56 | ||
| Q3 24 | $0.78 | $0.11 | ||
| Q2 24 | $0.73 | $0.51 | ||
| Q1 24 | $0.81 | $0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $21.7M |
| Total DebtLower is stronger | $608.7M | $286.7M |
| Stockholders' EquityBook value | $788.8M | $-17.3M |
| Total Assets | $1.6B | $403.2M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $21.7M | ||
| Q3 25 | $276.2M | $16.0M | ||
| Q2 25 | $231.8M | $17.1M | ||
| Q1 25 | $236.9M | $31.5M | ||
| Q4 24 | $221.6M | $33.5M | ||
| Q3 24 | $250.5M | $14.7M | ||
| Q2 24 | $217.8M | $7.5M | ||
| Q1 24 | $289.6M | $17.1M |
| Q4 25 | $608.7M | $286.7M | ||
| Q3 25 | $608.6M | $308.4M | ||
| Q2 25 | $607.7M | $310.9M | ||
| Q1 25 | $603.9M | $280.7M | ||
| Q4 24 | $601.6M | $280.4M | ||
| Q3 24 | $596.4M | $280.2M | ||
| Q2 24 | $586.9M | $269.7M | ||
| Q1 24 | $594.0M | $265.3M |
| Q4 25 | $788.8M | $-17.3M | ||
| Q3 25 | $776.7M | $-25.7M | ||
| Q2 25 | $757.5M | $-29.0M | ||
| Q1 25 | $751.3M | $-29.7M | ||
| Q4 24 | $732.3M | $-35.6M | ||
| Q3 24 | $727.7M | $-42.8M | ||
| Q2 24 | $713.3M | $-44.6M | ||
| Q1 24 | $672.4M | $-48.5M |
| Q4 25 | $1.6B | $403.2M | ||
| Q3 25 | $1.7B | $407.1M | ||
| Q2 25 | $1.6B | $399.8M | ||
| Q1 25 | $1.6B | $351.9M | ||
| Q4 24 | $1.6B | $349.7M | ||
| Q3 24 | $1.5B | $342.3M | ||
| Q2 24 | $1.5B | $321.4M | ||
| Q1 24 | $1.6B | $319.8M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $39.6M |
| Free Cash FlowOCF − Capex | $24.6M | $35.2M |
| FCF MarginFCF / Revenue | 13.4% | 23.0% |
| Capex IntensityCapex / Revenue | 4.5% | 2.9% |
| Cash ConversionOCF / Net Profit | 1.35× | 5.39× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $41.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $39.6M | ||
| Q3 25 | $52.6M | $10.0M | ||
| Q2 25 | $35.6M | $4.3M | ||
| Q1 25 | $35.1M | $5.6M | ||
| Q4 24 | $29.0M | $26.7M | ||
| Q3 24 | $60.0M | $12.5M | ||
| Q2 24 | $69.1M | $-4.8M | ||
| Q1 24 | $55.3M | $8.9M |
| Q4 25 | $24.6M | $35.2M | ||
| Q3 25 | $47.2M | $5.3M | ||
| Q2 25 | $25.0M | $533.0K | ||
| Q1 25 | $24.4M | $292.0K | ||
| Q4 24 | $16.6M | $21.6M | ||
| Q3 24 | $46.2M | $11.1M | ||
| Q2 24 | $63.1M | $-6.0M | ||
| Q1 24 | $46.5M | $7.4M |
| Q4 25 | 13.4% | 23.0% | ||
| Q3 25 | 24.6% | 3.8% | ||
| Q2 25 | 14.3% | 0.4% | ||
| Q1 25 | 14.3% | 0.2% | ||
| Q4 24 | 8.9% | 17.3% | ||
| Q3 24 | 24.1% | 8.9% | ||
| Q2 24 | 34.6% | -5.0% | ||
| Q1 24 | 27.1% | 6.6% |
| Q4 25 | 4.5% | 2.9% | ||
| Q3 25 | 2.8% | 3.4% | ||
| Q2 25 | 6.1% | 2.9% | ||
| Q1 25 | 6.3% | 4.3% | ||
| Q4 24 | 6.7% | 4.0% | ||
| Q3 24 | 7.2% | 1.2% | ||
| Q2 24 | 3.3% | 1.0% | ||
| Q1 24 | 5.1% | 1.3% |
| Q4 25 | 1.35× | 5.39× | ||
| Q3 25 | 3.03× | 4.32× | ||
| Q2 25 | 1.15× | 8.39× | ||
| Q1 25 | 1.39× | 1.17× | ||
| Q4 24 | 0.76× | 3.94× | ||
| Q3 24 | 1.48× | 9.70× | ||
| Q2 24 | 1.82× | -0.79× | ||
| Q1 24 | 1.28× | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PMTS
| US Debit And Credit | $128.9M | 84% |
| US Prepaid Debit | $24.4M | 16% |
